This is also true for studies of biomarkers to improve diagnosis of low grade dysplasia and determine disease progression through estimation of aneuploidy although this method has not yet been approved for routine use 14. Although esophagectomies are commonly accepted for management of patients with both high grade dysplasia and Barrett's esophagus, they have a 50% morbidity rate and 5% surgical mortality rate even at medical centers with great amounts of experience in this type of procedures 15,16. The most recent reports show that only 12% of these surgical specimens have invasive adenocarcinoma while it has also been demonstrated that surgical treatment and endoscopic treatment of this type of patients have the same survival rates 17,18.
Aunque la esofaguectomía es comúnmente aceptada para el manejo del paciente con displasia de alto grado sobre el EB, esta implica una morbilidad de 50% así como una mortalidad quirúrgica de 5% incluso en centros con alta experiencia en este tipo de procedimientos 15, 16; informes más recientes demuestran solo 12% de adenocarcinoma invasivo en el espécimen quirúrgico y se ha demostrado igual sobrevida al comparar el tratamiento quirúrgico frente al endoscópico en estos pacientes 17, 18; las lesiones intramucosas m1 y m2 no tienen posibilidad de compromiso ganglionar y hasta 4% en m3, han ocasionado que la resección endoscópica menos invasiva sea una alternativa válida para tratar esta condición 19.